The Compare-Acute trial is a prospective randomised trial in patients with multivessel disease, who are admitted into hospital with a ST-elevation Myocardial Infarction. The purpose of the study is to compare a FFR guided multivessel PCI taking place during the primary PCI with a primary PCI of the culprit vessel only. Patients will be enrolled after successful revascularisation of the culprit vessel. Patients that have at least one lesion with a diameter of stenosis of more than 50% on visual estimation, feasible (operators judgement) for treatment with PCI in a non-infarct related artery, will be randomised either to the FFR guided complete revascularisation arm or staged revascularisation by proven ischemia or persistence of symptoms of angina. Approximately 885 patients will be entered in the study. Study hypothesis: FFR-guided complete percutaneous revascularisation of all flow-limiting stenoses in the non-IRA performed within the same procedure as the primary PCI or within the same hospitalisation will improve clinical outcomes compared to the staged revascularisation, guided by prove of ischemia or clinical judgment, as recommended from the guidelines.
Background of the study: At the moment the general opinion is divided over the way the non culprit lesions in patients presenting with STEMI should be treated. While the previous guidelines stead that these lesions should be treated in a second time ( ie not during the primary intervention) the actual guidelines do not touch this argument. The reason is that the studies where the previous guidelines were based are old. Meanwhile small sized randomised trials from EU region have proven favourable outcomes with NON infarct related artery during the primary procedure while registers (non randomised trials) from USA still recommend the staged treatment. For this reason we have decided to perform a randomised study to address this issue incorporating the state of the art diagnosis and treatment, as well as the new medical therapy and PCI techniques. Objective of the study: FFR-guided complete percutaneous revascularisation of all flow-limiting stenoses in the non-IRA performed within the same procedure as the primary PCI or within the same hospitalisation will improve clinical outcomes compared to the staged revascularisation, guided by prove of ischemia or clinical judgment, as recommended from the guidelines Study design: Prospective, 1: 2 randomisation. FFR guided revascularisation during primary PCI (1) versus following actual guidelines (2) Study population: All STEMI patients between 18-85 years who will be treated with primary PCI in \< 12 h (more than 12 hr if persisting pain allowed) after the onset of symptoms and have at least one stenosis of \>50% in a non-IRA judged feasible for treatment with PCI. Intervention (if applicable): FFR-guided complete percutaneous revascularisation of all flow-limiting stenoses in the non-IRA performed within the same procedure as the primary PCI or within the same hospitalisation will improve clinical outcomes compared to the staged revascularisation, guided by prove of ischemia or clinical judgment, as recommended from the guidelines Primary study parameters/outcome of the study: Composite endpoint of all cause mortality non-fatal Myocardial Infarction, any Revascularisation and Stroke (MACCE) at 12 months
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
885
FFR-guided revascularisation strategy
Staged revascularisation by proven ischemia or persistence of symptoms of angina
University Hospital BRNO
Brno, Czechia
University Hospital Hradec Králové
Hradec Králové, Czechia
Liberec Regional Hospital
Liberec, Czechia
Herz-Zentrum Bad Krozingen
Bad Krozingen, Germany
Herzzentrum Bad Segeberger Klinik
Bad Segeberg, Germany
Klinikum Links der Weser
Bremen, Germany
Medizinische Klinik IV
Ingolstadt, Germany
Medical University Rostock
Rostock, Germany
Gottsegen György Országos Kardiológiai Intézet
Budapest, Hungary
Szabolcs - Szatmár - Bereg County Hospitals and University Teaching Hospital
Nyíregyháza, Hungary
...and 16 more locations
Number of Participants With the Composite Endpoint of MACCE
Number of participants with the composite endpoint of all cause mortality non-fatal Myocardial Infarction, any Revascularisation and Cerebrovascular Events (MACCE) at 12 months between groups
Time frame: 12 months
Number of Participants With Death From Any Cause
Number of participants with all cause mortality at 12 months between groups
Time frame: 12 months
Number of Participants With Cardiac Death
Number of participants with Cardiac mortality at 12 months between groups
Time frame: 12 months
Number of Participants With Spontaneous MI
Number of participants with Spontaneous Myocardial Infarction at 12 months between groups
Time frame: 12 months
Number of Participants With Periprocedural MI
Number of participants with Periprocedural Myocardial Infarction at 12 months between groups
Time frame: 12 months
Number of Participants With Revascularization - PCI
Number of participants with revascularization PCI at 12 months between groups
Time frame: 12 months
Number of Participants With Revascularization - CABG
Number of participants with revascularization CABG at 12 months between groups
Time frame: 12 months
Number of Participants With Cerebrovascular Event
Number of participants with Cerebrovascular event at 12 months between groups
Time frame: 12 months
Number of Participants With Composite Endpoint of NACE (Any First Event)
Number of participants with Composite endpoint of Cardiac death, Myocardial Infarction, any Revascularisation, Stroke and Major bleeding at 12 months (NACE i.e. Net Adverse Clinical Events)
Time frame: 12 months
Number of Participants With Death From Any Cause or MI
Number of participants with Part of composite NACE-Death from any cause or Myocardial Infarction at 12 months
Time frame: 12 months
Number of Participants With Major Bleeding
Number of participants with Major bleeding at 12 months - Part of composite NACE
Time frame: 12 months
Number of Participants With Any Bleeding at 12 Months
Number of participants with any bleeding at 12 months - part of composite endpoint NACE
Time frame: 12 months
Number of Participants With Any Bleeding at 48 Hours
Number of participants with any bleeding at 48 hours - part of composite endpoint NACE
Time frame: 48 hours
Number of Participants With Hospitalization
Number of participants with hospitalization for heart failure, unstable angina or chest pain
Time frame: 12 months
Number of Participants With Revascularization
Number of participants with any revascularization-Part of composite endpoint NACE
Time frame: 12 months
Number of Participants With Stent Thrombosis
Number of participants with Stent Thrombosis - Part of composite endpoint NACE
Time frame: 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Number of Participants With Primary Endpoint Outcome MACCE (Any First Event) at 3 Year
Number of participants with Composite primary endpoint MACCE (any first event) at 3 year
Time frame: 3 year
Number of Participants With All Cause Death at 3 Year
Number of participants with Composite endpoint MACCE (any first event) at 3 year - all cause death
Time frame: 3 year
Number of Participants With Cardiac Death at 3 Year
Number of participants with Composite endpoint MACCE (any first event) at 3 year - Cardiac death
Time frame: 3 year
Number of Participants With Spontaneous MI at 3 Year
Number of participants with Composite endpoint MACCE (any first event) at 3 year - Spontaneous MI
Time frame: 3 year
Number of Participants With Peri-procedural MI at 3 Year
Number of participants with Composite endpoint MACCE (any first event) at 3 year - Peri-procedural MI
Time frame: 3 year
Number of Participants With Urgent Revascularization at 3 Year
Number of participants with Composite endpoint MACCE (any first event) at 3 year - urgent revascularisation
Time frame: 3 year
Number of Participants With Elective Revascularization at 3 Year
Number of participants with Composite endpoint MACCE (any first event) at 3 year -elective revascularisation
Time frame: 3 year
Number of Participants With Cerebrovascular Event
Number of participants with Composite endpoint MACCE (any first event) at 3 year -Cerebrovascular event
Time frame: 3 year
Number of Participants With Composite Endpoint of NACE (Any First Event) at 3 Year
Number of participants with Composite endpoint of Cardiac death, Myocardial Infarction, any Revascularisation, Stroke and Major bleeding at 3 year (NACE i.e. Net Adverse Clinical Events)
Time frame: 3 years
Number of Participants With Death From Any Cause or MI
Number of participants with Part of composite NACE-Death from any cause or Myocardial Infarction at 3 year
Time frame: 3 year
Number of Participants With Major Bleeding at 3 Year
Number of participants with Part of composite endpoint NACE- Major bleeding at 3 year
Time frame: 3 year
Number of Participants With Hospitalization
Number of participants with Hospitalization for heart failure, unstable angina, MI
Time frame: 3 year
Number of Participants With Hospitalization at 3 Year
Number of participants with Hospitalization for heart failure, unstable angina, MI and/or chest pain
Time frame: 3 year
Number of Participants With Stent Thrombosis at 3 Year
Number of participants with Stent Thrombosis at 3 year - Part of composite endpoint NACE
Time frame: 3 year
Number of Participants With Any Bleeding at 3 Year
Number of participants with any bleeding at 3 year - Part of composite endpoint NACE
Time frame: 3 year